[慢性肝病患者血清中可溶性白细胞介素-6受体、可溶性糖蛋白130的检测与评估]

[Examination and evaluation of sIL-6R, sgp130 in serum in patients with chronic hepatopathy].

作者信息

Shang J, Xu Y, Zhang H

机构信息

Department of Digestive Disease, Peoples' Hospital of Henan Province, Zhengzhou 450003, China.

出版信息

Zhonghua Gan Zang Bing Za Zhi. 2000 Apr;8(2):87-8.

PMID:10861111

Abstract

OBJECTIVE

To observe the variation of soluble interleukin-6 receptor (sIL-6R) and soluble interleukin-6 receptor beta strands (sgp130) in patients with chronic hepatopath.

METHODS

We examined sIL-6R and sgp130 level in 40 patients with chronic hepatitis (CH), 15 with cirrhosis following hepatitis, and 35 normal controls (NC) in serum by enzyme linked immunosorbent assay (ELISA) method.

RESULTS

The content of sIL-6R and sgp130 in serum was higher in CH group (224.27 mug/L and 489.35 mug/L, respectively) than NC group (174.81 mug/L and 273.64 mug/L respectively). The two parameters above in patients with hepatocirrhosis were higher than those in patients with chronic hepatitis, and the content in order of quantity was severe>moderate>slight. There was significant difference among the three groups (P<0.05, P<0.01), and positive correlation between sIL-6R and sgp130 level (r=0.481, P<0.05), between sIL-6R, sgp130 level and total bilirubin level (r=0.417, r=0. 428, P<0.01). While sIL-6R, sgp130 was no significant correlation to ALT (r=0.173, r=0.182, P>0.05).

CONCLUSION

sIL-6R and sgp130 in serum are associated with the development of chronic hepatopath, and therefore can guide the assessment of prognosis.

摘要

目的

观察慢性肝病患者可溶性白细胞介素-6受体（sIL-6R）和可溶性白细胞介素-6受体β链（sgp130）的变化。

方法

采用酶联免疫吸附测定（ELISA）法检测40例慢性肝炎（CH）患者、15例肝炎后肝硬化患者及35例正常对照（NC）血清中的sIL-6R和sgp130水平。

结果

CH组血清中sIL-6R和sgp130含量（分别为224.27μg/L和489.35μg/L）高于NC组（分别为174.81μg/L和273.64μg/L）。肝硬化患者上述两项指标高于慢性肝炎患者，且含量严重程度顺序为重度>中度>轻度。三组间差异有统计学意义（P<0.05，P<0.01），sIL-6R与sgp130水平呈正相关（r=0.481，P<0.05），sIL-6R、sgp130水平与总胆红素水平呈正相关（r=0.417，r=0.428，P<0.01）。而sIL-6R、sgp130与ALT无显著相关性（r=0.173，r=0.182，P>0.05）。